Enveda raises $311M at $2B valuation to push nature-based AI drugs into trials
The new funding doubles Enveda’s valuation in a year as it advances plant- and microbe-derived drug candidates in patient studies.
The new funding doubles Enveda’s valuation in a year as it advances plant- and microbe-derived drug candidates in patient studies.
The voice AI provider’s mix of big enterprises and creators shows how synthetic agents are moving into mainstream customer support and media work.
The two venture firms are arming themselves with fresh capital for AI deals, from early-stage to growth rounds and across India and Southeast Asia.
The funding backs Ema’s push to replace parts of traditional SaaS and IT services with task-based AI automation.
Most of the package is available now, with Nvidia’s $1 billion due in mid-November.
New funding and technical support aim to expand AI-based climate and crop advice across the Global South.
Huge compute and infrastructure spending forces OpenAI to seek more capital while pushing back its listing.